Litcius/Paper detail

miR-623 suppresses cell proliferation, migration and invasion through direct inhibition of XRCC5 in breast cancer

Qing Li, Jiangtao Liu, Yanli Jia, Tingting Li, Mei Zhang

2020Aging19 citationsDOIOpen Access PDF

Abstract

BACKGROUND/AIMS: MicroRNAs (miRNAs) are short, non-coding RNA molecules that control gene expression trough negative translational regulation. MiR-623 is a tumor suppressor, and it's function and mechanism in breast cancer has not been reported. RESULTS: Exogenous overexpression of miR-623 suppressed cell proliferation, migration and invasion, meanwhile, but promoted cell apoptosis. MiR-623 knockdown displayed opposite results. Overexpression of miR-623 resulted in the downregulation of CDK4/6 as well as the inhibition of the phosphatidylinositol-3-kinase (PI3K)/Akt and Wnt/β-Catenin signaling pathways. MiR-623 knockdown displayed opposite results. Results of the reporter assay revealed that the luciferase activity was decreased in XRCC5-wt cells, suggesting that miR-623 could directly combine with 3' UTR of XRCC5. MiR-623 significantly suppressed XRCC5 expression, which is critical for miR-623-induced proliferation and migration block in breast cancer cells. CONCLUSION: miR-623 suppressed cell proliferation, migration and invasion through downregulation of cyclin dependent kinases and inhibition of the phosphatidylinositol-3-kinase (PI3K)/Akt and Wnt/β-Catenin pathways by targeting XRCC5. METHODS: miR-623 was either overexpressed in breast cancer cell lines through exogenous transfection or knocked down by specific siRNA. Cell proliferation, migration and invasion were examined using CCK-8, colony formation and transwell assay. The direct target of miR-623 was verified using luciferase reporter gene assay.

Topics & Concepts

Cell growthCancer researchBreast cancerCancerOncologyBiologyInternal medicineMedicineGeneticsMicroRNA in disease regulationCircular RNAs in diseasesCancer Mechanisms and Therapy
miR-623 suppresses cell proliferation, migration and invasion through direct inhibition of XRCC5 in breast cancer | Litcius